Tag: pharmaceuticals
-
PBS to Air Documentary on Vaccine Attitudes and Disease
4 September 2014. Public Broadcasting Service (PBS) will air a documentary next week on the changing public attitudes toward vaccines and their effects on the growing occurrence of communicable diseases in the U.S. The show, Vaccines — Calling the Shots premieres on PBS as part of the NOVA series of science documentaries on Wednesday 10…
-
Calico, AbbVie Partner on Aging Disorder Therapies
3 September 2014. California Life Sciences LLC, better known as Calico, and the pharmaceutical company AbbVie Inc. are collaborating on discovery and commercialization of drugs for age-related diseases such as cancer and neurodegenerative disorders. The partnership, which includes building a new research center, could result in a joint investment as high as $1.5 billion. Calico,…
-
Multi-Purpose Drug Boosts Adherence After Heart Attack
3 September 2014. Researchers at Mount Sinai Hospital in New York and National Centre for Cardiovascular Research in Madrid, Spain found a pill combining three cardiovascular drugs usually prescribed separately helps heart attack patients stick to their medications better than the three drugs taken separately. The team led by Valentin Fuster, accredited to both institutions,…
-
Breakthrough Status Given Parkinson’s Psychosis Drug
2 September 2014. Acadia Pharmaceuticals says the U.S. Food and Drug Administration designated its drug candidate pimavanserin as a breakthrough therapy for the treatment of psychosis associated with Parkinson’s disease. Acadia is a biopharmaceutical company in San Diego specializing in neurological and central nervous system disorders. Pimavanserin is Acadia’s lead therapy candidate, to be offered…
-
Ebola Vaccine Safety Trials Scheduled in U.S., U.K., Africa
28 August 2014. Early-stage clinical trials testing the safety of new vaccines to protect against the Ebola virus are scheduled to begin as early as next week at sites in the U.S., United Kingdom, Mali, and The Gambia in West Africa. The vaccines are being developed by National Institute of Allergy and Infectious Diseases (NIAID),…
-
Biotech, Universities to Test Hydrogel for Vocal Fold Scars
28 August 2014. BioTime Inc., a biotechnology company in Alameida, California, is partnering with researchers at University of Wisconsin and Université catholique de Louvain in Belgium to test its hydrogels for treating vocal cord scarring, a voice problem that results from injury or disease. Financial terms of the collaboration were not disclosed. Vocal folds are…
-
Ionic Liquids Shown to Combat Bacterial Biofilms
27 August 2014. Researchers at Los Alamos National Lab in New Mexico developed a way to harness ionic liquids — salts in a liquid state — that in lab tests disrupt biofilms, antibiotic-resistant bacterial colonies, and boost treatments for skin infections. The team led by Los Alamos Lab’s David Fox and Samir Mitragotri at University…
-
FDA Approves Low-Dose Anti-Inflammatory for Arthritis Pain
25 August 2014. Iroko Pharmaceuticals LLC in Philadelphia says the U.S. Food and Drug Administration approved its low-dose formulation of the nonsteroidal anti-inflammatory drug diclofenac to treat pain from osteoarthritis. FDA in October 2013 already approved this drug, marketed under the name Zorvolex, as a treatment for mild to moderate pain in adults. Osteoarthritis is…
-
Trial Crowdsources Lung Cancer Biomarker Screening
22 August 2014. A clinical trial at University of Colorado Cancer Center in Aurora is recruiting participants through an online campaign to find people with lung cancer that meet a specific genetic profile who would most likely respond to the drug being tested. The study is led by Ross Camidge, director of the center’s thoracic…
-
Extended Hemophilia Therapy Lowers Bleeding Rates in Trial
22 August 2014. Results from a late-stage clinical trial show an extended-life therapy to control hemophilia reduces rates of bleeding among patients when used as a preventive medication. The biologic tested in the trial is an extended release version of Advate, an engineered form of blood coagulant proteins made by Illinois-based drug maker Baxter International…